Oskar Slotboom
Director/Miembro de la Junta en Varmx BV .
Cargos activos de Oskar Slotboom
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Biogeneration Management BV
Biogeneration Management BV Investment ManagersFinance Biogeneration Management is a venture capital firm, a subsidiary of BioGeneration Holding BV and was founded in 2006. Biogeneration management is headquartered in Naarden. | Inversor de Capital Privado | 01/07/2016 | - |
Mellon Medical BV
Mellon Medical BV Medical SpecialtiesHealth Technology Mellon Medical BV manufactures and develops surgical suturing devices. The firm’s suturing device, the Switch, is designed for surgeons who perform the challenging operations and can easily be rotated in the hand because of its pencil-like shape. The company was founded in April 2013 by Mark Vrancken Peeters and is headquartered in Nijmegen, the Netherlands. | Director/Miembro de la Junta | - | - |
Varmx BV
Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018. | Director/Miembro de la Junta | - | - |
Dunad Therapeutics Ltd.
Dunad Therapeutics Ltd. BiotechnologyHealth Technology Dunad Therapeutics Ltd. is a British biopharmaceutical company that specializes in developing targeted protein degradation therapies. Dunad was founded in 2020 and is headquartered in an undisclosed location, with operations in both the UK and the US. The company's platform allows for selective degradation through direct target modification using tuneable mono-valent small molecules, which enables the development of more drug-like, orally bioavailable, and CNS-accessible protein degraders. The company is backed by Epidarex Capital. Pearl Shirley Huang has been the CEO of the company since 2022. | Director/Miembro de la Junta | - | - |
Historial de carrera de Oskar Slotboom
Antiguos cargos conocidos de Oskar Slotboom.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Crucell NV
Crucell NV Pharmaceuticals: MajorHealth Technology Crucell NV develops, produces and markets vaccines, proteins and antibodies that prevent and treat infectious diseases. It focuses in the research & development of innovative immunization candidates to fight against tuberculosis, malaria, HIV/AIDS, influenza, rabies, polio and several other diseases which are the global health problems. The firms prod8ucts include Quinvaxem, Epaxal, Hepavax-Gene, Vivotif and Dukoral against paediatric, respiratory and travel or endemic infections. The company was founded by Domenico Valerio on October 9, 2000 and is headquartered in Leiden, Netherlands. | Corporate Officer/Principal | - | - |
AVANTIUM N.V. | Corporate Officer/Principal | 01/09/2014 | - |
Formación de Oskar Slotboom.
INSEAD | Masters Business Admin |
University of Twente | Graduate Degree |
Estadísticas
Internacional
Países Bajos | 7 |
Francia | 2 |
Reino Unido | 2 |
Operativa
Director/Board Member | 3 |
Corporate Officer/Principal | 2 |
Graduate Degree | 1 |
Sectorial
Health Technology | 5 |
Consumer Services | 3 |
Finance | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
AVANTIUM N.V. | Producer Manufacturing |
Empresas privadas | 5 |
---|---|
Crucell NV
Crucell NV Pharmaceuticals: MajorHealth Technology Crucell NV develops, produces and markets vaccines, proteins and antibodies that prevent and treat infectious diseases. It focuses in the research & development of innovative immunization candidates to fight against tuberculosis, malaria, HIV/AIDS, influenza, rabies, polio and several other diseases which are the global health problems. The firms prod8ucts include Quinvaxem, Epaxal, Hepavax-Gene, Vivotif and Dukoral against paediatric, respiratory and travel or endemic infections. The company was founded by Domenico Valerio on October 9, 2000 and is headquartered in Leiden, Netherlands. | Health Technology |
Biogeneration Management BV
Biogeneration Management BV Investment ManagersFinance Biogeneration Management is a venture capital firm, a subsidiary of BioGeneration Holding BV and was founded in 2006. Biogeneration management is headquartered in Naarden. | Finance |
Mellon Medical BV
Mellon Medical BV Medical SpecialtiesHealth Technology Mellon Medical BV manufactures and develops surgical suturing devices. The firm’s suturing device, the Switch, is designed for surgeons who perform the challenging operations and can easily be rotated in the hand because of its pencil-like shape. The company was founded in April 2013 by Mark Vrancken Peeters and is headquartered in Nijmegen, the Netherlands. | Health Technology |
Varmx BV
Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018. | Health Technology |
Dunad Therapeutics Ltd.
Dunad Therapeutics Ltd. BiotechnologyHealth Technology Dunad Therapeutics Ltd. is a British biopharmaceutical company that specializes in developing targeted protein degradation therapies. Dunad was founded in 2020 and is headquartered in an undisclosed location, with operations in both the UK and the US. The company's platform allows for selective degradation through direct target modification using tuneable mono-valent small molecules, which enables the development of more drug-like, orally bioavailable, and CNS-accessible protein degraders. The company is backed by Epidarex Capital. Pearl Shirley Huang has been the CEO of the company since 2022. | Health Technology |
- Bolsa de valores
- Insiders
- Oskar Slotboom
- Experiencia